8/31/26
ShockWave Medical (SWAV)
ThesisThe recent strategic partnerships and promising clinical trial results are enhancing investor confidence in ShockWave's growth trajectory.
★ Analysts see FY2024 revenue reaching $922M — +26.2% growth in a single year.
Why Revenue Could Accelerate
- 01ShockWave's recent partnership with a major healthcare provider could accelerate IVL adoption, potentially increasing revenue by 30% over the next year.
- 02The company is exploring new indications for its IVL technology, which could expand its addressable market by an estimated $1.5B.
- 03Recent clinical trial results demonstrating improved patient outcomes could enhance the company's market position and lead to increased sales.
- 04Minimally invasive surgical techniques
- 05Growth in cardiovascular disease prevalence
- 06Adoption rates of IVL technology in hospitals and outpatient centers
- 07Regulatory approvals for new product indications
- 08Expansion into international markets, particularly Europe and Asia
My Notes
- "Our innovative technology is gaining traction, and we are excited about the future opportunities in the cardiovascular market."
- Moat: ShockWave's patented IVL technology provides a significant barrier to entry, protecting its market position.
- growth - Investors are likely attracted to the high revenue growth potential and innovative technology.
- Interest rates can affect the company's cost of capital and financing for expansion…
- Watch on earnings: Adoption rate of IVL technology in new hospitals, Quarterly revenue growth, Gross margin trends.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $922M to $1.1B as shockwave's recent partnership with a major healthcare provider could accelerate ivl adoption.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.